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Abstract: The main goal of the work reported here was to determine the degree of oxidative/alkali-labile DNA 
damages in peripheral blood as well as in the blood stasis from varicose vein of (chronic venous disorder) CVD patients. 
Moreover, determination of the impact of Detralex usage on the level of (oxidative) DNA damages in CVD patients was 
evaluated as well.
The degree of oxidative DNA damages was studied in a group consisted of thirty patients with diagnosed chronic venous 
insufficiency (CVI) in the 2nd and 3rd degree, according to clinical state, etiology, anatomy and pathophysiology 
(CEAP), and qualified to surgical procedure. The control group consisted of normal volunteers (blood donors) qualified 
during standard examinations at Regional Centers of Blood Donation and Blood Therapy.
The comet assay was used for determination of DNA damages.
Analyses of the obtained results showed increase in the level of oxidative/alkali-labile DNA damages in lymphocytes 
originating from antebrachial blood of CVD patients as compared to the control group (Control) (p < 0.002; ANOVA). In 
addition, it was demonstrated that the usage of Detralex® resulted in decrease of the level of oxidative/alkali-labile DNA 
damages in CVD patients as compared to patients without Detralex® treatment (p < 0.001; ANOVA).
Based on findings from the study, it may be hypothesized about occurrence of significant oxidative DNA damages as the 
consequence of strong oxidative stress in CVD. In addition, antioxidative effectiveness of Detralexu® was observed at the 
recommended dose, one tablet twice daily.
Keywords: Reactive oxygen species (ROS), chronic venous insufficiency (CVI), micronized purified flavonoid fraction 
(MPFF).
INTRODUCTION
Chronic venous diseases (CVDs) represent one of the 
oldest known chronic human illnesses. Earliest data describ­
ing varicose veins, one of the main syndromes of chronic 
venous insufficiency (CVI) and its treatment are dated to 
antiquity [1].
Within theories trying to explain the development of 
chronic venous inefficiency, the key role is played by the 
“leukocyte trap” . In this phenomenon, highly significant role 
is played by reactive oxygen species (ROS) and reactive 
nitrogen species (RNS). Superoxide anion (O2-% hydroxyl 
radical (OH ), hydroperoxide radical (HO2 ), hydroxy peroxide
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(H2O2), oxygen singlet (O2 ) take part in damaging peri- 
tissue structures [2]. Oxidative damage of deoxyribonucleic 
acid occurs because of hydroxyl radical (O H ) action. This 
phenomenon is explained by two concepts. The first concept 
says about reaction of genetic material with OH', which was 
generated in Fenton reaction with participation of Cu1+ or 
Fe2+ ions. The second concept indicates on elevated intracel­
lular level of free Ca2+ ions, which results in activation of 
Ca2+-depandant nucleases responsible for DNA degradation 
[3, 4]. Initiated oxidative DNA damages cause instability of 
genetic material because of mutation and it finally can result 
in cell death.
Human organisms try to be protected from oxidative 
changes in different ways. On the level of DNA, the protec­
tion is based on two mechanisms of elimination of free radi­
cal-induced DNA damages. The first of them, base-excision 
repair (BER) removes modified nucleotide bases by hydroly­
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sis of N-glycosidic bond through mono- and bifunctional 
glycosylases. Monofunctional glycosylases break the bond 
between impaired nucleoside base and deoxyribose moiety 
causing generation of non-purine and non-pyrimidine sites. 
Besides the removal of modified base and generation of non­
purine and non-pyrimidine sites, bifunctional glycosylases 
have lyase properties, which enable removal of above­
mentioned sites through P -  termination. After this mecha­
nism, a singe nucleotide gap is left in DNA structure. On the 
other side, NER mechanism is not as specific as BER 
mechanism and requires a lot of energy by ATP hydrolysis. 
Following modifications in DNA conformation are removed 
through NER mechanism: photodimers, pyrimidins, adducts 
with different substitute, such as 1, N2-propano 2'- 
deoxyguanosine adduct. The NER mechanism relies on 
cleaving of improper fragment containing damage by nucle­
ase and elimination of this fragment [5].
Difference between these two repairing mechanisms 
relies on the fact that BER repairs DNA damages, which 
does not affect the DNA helical structure, whereas NER is 
an active mechanism towards damages, which change DNA 
conformation.
In pharmacotherapy of CVI, drugs of natural origin 
are applied. Detralex (450 mg of diosmin and 50 mg of 
hesperidin) plays a key role here. In other countries, 
this drug is marketed under a name Daflon 500. The 
effectiveness of the drug has been studied and confirmed in 
numerous clinical trials, including RELIFE trial that covered 
23 countries [6].
THE AIM OF THE WORK
The aim of the work was verification of research hy­
pothesis if the level of DNA damages (alkali-labile/oxidative 
damages) in peripheral blood lymphocytes (PBL) of patients 
with chronic venous disease is higher than in a control group 
(normal population).
Besides, we were trying to answer the question if therapy 
with phlebotropic drug (Detralex) of CVI patients is corre­
lated in any way with decrease in the level of these damages.
MATERIALS & METHODS
Degree of oxidative DNA damages was studied in a 
group that consisted of ten patients with diagnosed with 
chronic venous insufficiency, in the 2nd and 3rd degree, ac­
cording to clinical state, etiology, anatomy and pathophysi­
ology (CEAP). These patients were qualified for surgical 
procedure from February to May 2010 at the II Department 
of General Surgery in Cracow. Patient’s qualification for the 
study was carried out by phlebologist during ultrasonogra­
phy (USG) examination of venous vessels of lower limbs 
(DOPPLER).
The Bioethical Committee of the Jagiellonian University 
in Cracow (KBET/162/B/2009) expressed positive approval 
about the study.
The control group consisted of 30 normal volunteers 
(blood donors) qualified during standard examinations at 
Regional Centers of Blood Donation and Blood Therapy. 
The Comet assay, electrophoresis of individual cells on
agarose gels were employed for the determination of 
DNA damages [7]. The cell viability assay with fluorescein 
diacetate (FDA) and ethidium bromide (EtBr) were used to 
evaluate the viability of cells before every study [8]. Cell 
viability was above 95%.
Isolation of Lymphocytes from Peripheral and Stasis 
Blood
Venous blood was collected from sick and normal donors 
to polypropylene tubes containing K2EDTA (1.5 mg/1 ml), 
stratified mildly along the wall of the Histopaqu-1077 tube 
(1:1 ratio) creating a density gradient. Then, it was centri­
fuged at room temperature for 40 minutes, 400 x g. After 
mild centrifugation, application of circular movement, the 
lymphocyte layer (Fig. 1) was transferred to polypropylene 
tubes (Falcon). Cold PBS free of Ca2+ and Mg2+ ions was 
added to collected lymphocytes and the whole mixture was 
centrifuged at 4°C for 10 min at 700 x g. This step was re­
peated twice. The cells were counted with the use of Bürker 
chamber and suspended later in 2 x 106 cells/ml concentra­
tion of PBS. Such prepared cell suspension was frozen 
at -80°C in a box filled out with isopropanol in a medium 
containing 90% FBS+10% DMSO.
Fig. (1). Density gradient centrifugation.
Cells Viability
For the determination of the number of live cells, 25 pl of 
working solution [25 pl FDA in acetone (5 mg/ml), 350 pl 
EtBr (10 x diluted in PBS) and 4.8 ml PBS] was added to the 
total volume of 20 pl (1 drop) of cell suspension. Five min­
utes later, the number of live cells was estimated on slides 
under fluorescence microscope with the use of a blue filter. 
The total number of cells, as well as the total number of live 
cells was determined as the percentage of live cells. The live 
cells were dyed with fluorescein on green color and the nu­
clei of dead cells were dyed with ethidium bromide on or­
ange color (Figs. 2 and 3). At least 200 cells were counted on 
each section.
Fig. (2). Determination of cell viability.
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Fig. (3). Working model of FDA test: fluorescein is aggregated in 
cells with intact cell membrane; a fluorescein is leaking out from cells 
with discontinue membrane, ethidium bromide is binding to nucleic 
acids. Image from fluorescence microscopy (10x magnitude): nuclei 
of dead cells (red color) stained with ethidium bromide.
Alkaline Electrophoresis of Individual Cells in Agarose 
Gel by Comet Method
Oxidative DNA damages are studied by electrophoresis 
of single cell in agarose gel [7]. Determination of the oxida­
tive damages is based on the detection of 8-oxoguanine with 
the use of formamidopyrimidine DNA glycosylase (Fpg) [9].
During the first stage of the study, sections were pre­
pared. For this purpose, previously isolated and frozen (at - 
80° C) lymphocytes were defrosted in a water bath at 36° C, 
which allowed to keep high cell viability (above 95%). Then, 
the cells were suspended in cold PBS (4° C) and total con­
centration of 1.5 x 106 cells/ml was obtained. Such prepared 
samples were centrifuged at 230 x g for 8 min at 4° C (a cen­
trifuge with horizontal rotor). Washing with PBS was re­
peated thrice, keeping the same conditions as mentioned 
above.
The cell suspension (30,000 cells) at volume of 85 pl was 
re-suspended in 225 pl (0.5%) of low melting point agarose 
(LMPA) and left in a water bath (37° C). Then, the volume 
of 100 pl of cells in agarose were smeared on slides, which 
were earlier coated with thin layer (100 pl) of 0.5% normal 
melting point agarose (NMPA) and left to dry out. The slides 
were covered with cover slips and placed on the ice. After 10 
min, the cover slips were removed, and slides were placed in 
the lysis buffer (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 
pH 10, with addition of 1% Triton X -100 and 10% DMSO) 
for 1h at 4° C in dark to eliminate extra DNA damages.
After lysis, sections were placed in re-distillated water 
and washed twice with cold HEPES buffer (40 mM HEPES;
0.1 M KCl; 0.5 mM EDTA; 0.2 mg/ml BSA, pH 8.0 with 
KOH; 10x concentrated stored at -20° C). An optimal envi­
ronment for enzyme action (formamidopyrimidine DNA 
glycosylase) was reached. On each section was dropped 50 
pl of Fpg, 0.1 U/ml. Slides with only HEPES buffer were 
used as the control.
Such prepared sections were covered with cover slips and 
placed in humid chamber at 37°C for 30 min. After incuba­
tion, the slides were placed in the apparatus for horizontal
electrophoresis and left for 40 min in a buffer for electropho­
resis (1 mM EDTA, 300 mM NaOH pH > 13) at 4° C to 
loosen nuclear super-coiled DNA. The sections were sub­
jected to low-voltage electrophoresis at 300 mA, 0.74 V/cm 
for 30 min at 4° C [10]. All the stages of the experiment were 
carried out in dark to eliminate any extra DNA damages. 
After gel electrophoresis, the slides were washed three times 
with neutral cold buffer (0.4 M Tris, pH 7.5, 4° C), and 
placed in cold 100% methanol for 5 min to fix the sections 
and then left to dry out. Sections prepared in this way can be 
stored for a long time (months and even years). Prior to 
analysis under fluorescent microscope, the sections were 
submerged for 5 min in re-distilled water and stained with 
propidium iodide at concentration of 2.5 pg/ml. For visuali­
zation of DNA damages, the epifluerescence microscope 
(Olympus IX-50) equipped with the source of fluorescence 
was used. The analysis of oxidative DNA damages was car­
ried out with the COMET PLUS 2.9 software (Comet Plus, 
Theta System Gmbh, Germany). The most frequently used 
parameter for the determination of DNA damages was the 
percentage content of DNA in the comet’s tail. These data 
were collected for 70 random images of comets obtained 
from slide. The analysis were done in two replicates (Fig. 4).
RESULTS
Hypothesis about the effect of CVI on alkali-labile DNA 
damages of lymphocytes from human blood was confirmed.
The CVI patients demonstrated significantly higher level 
of alkali-labile DNA damages in PBLs as compared to the 
control group (normal patients) (p < 0.001, U Mann-Whitney 
test) (Fig. 5).
Similar results were obtained at the level of oxidative 
DNA damages. The CVI patients demonstrated significantly 
higher level of oxidative DNA damages as compared to 
the control group (p < 0.001, U Mann-Whitney test) (Figs. 6 
and 7).
Patients applying Detralex (one tablet twice a day) dem­
onstrated significantly lower level of alkali-labile/oxidative 
DNA damages than patients who did not take the drug (p <
0.001; ANOVA rang Kruskala-Wallis) (Figs. 8 and 9). The 
level of alkali-labile DNA damages in PBLs from normal 
donors was significantly lower than the alkali-labile DNA 
damages in PBLs from CVI patients (Fig. 8) as well as in 
relation to alkali-labile DNA damages of blood stasis lym­
phocytes (BSL) originating from varicose vein CVI patients 
(p  < 0,0001; a N o V A  rang Kruskala-Wallis)
DISCUSSION 
1. Effect of CVI on DNA Damages in Human Blood 
Lymphocytes
Hypothesis about the effect of CVI on alkali-labile DNA 
damages in human blood lymphocytes was confirmed. 
Besides a number of biochemical changes, chronic venous 
insufficiency also increased the number of oxidative dam­
ages in purine bases, mainly 8-oxoguanine, 2, 6-diamino- 
4hydroxyl-5-formamidopirymidine, 4, 6-diamino-5 -  for- 
mamidopirimidine recognized by formamidopirimidine 
glycolicase.
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Fig. (4). Schematic representation of the comet assay incorporating lesion-specific formamidopyrimidine DNA glycosylase (Fpg).
Differences between DNA damages in PBLs from nor­
mal patients (donors o f blood for Regional Centers o f Blood 
Donation and Blood Therapy) in comparison to CVI patients 
were statistically significant. Similar situation concerned 
stasis blood from varicose vein, where increase in DNA 
damages in CVI patients was observed. Differences between 
DNA damages in PBLs from normal patients and BSLs from 
CVI patients were statistically significant. Moreover, DNA 
damages in BSLs from varicose veins were higher than in 
PBLs from the same CVI patients. These differences were 
statistically significant as well.
Obtained results seem to be unique; because no paper 
was found in an electronic database presenting observed by 
us effect o f CVI on DNA damages.
Cooke M. et al. demonstrated that cleavage o f super­
coiled, double-stranded DNA occurred during carcinogene­
sis, inflammation, and cardiac diseases. Formation o f O -2 
and H2O2 by xanthine oxidase (XO) increased during reper­
fusion after hypoxia in cardiac disease. Development o f CVI 
involves many different stages. Organic peroxides and H2O2 
are promoters o f inflammation process o f diseases with pro- 
inflammatory character. It was observed that chronic in­
flammation could be conducive in the process o f carcino­
genesis. It was shown that induced granulocytes could dam­
age DNA o f neighboring cells. This occurred during in­
flammation process in various diseases, when phagocytes 
release ROS not only to phagosomes but also outside the 
cell. Part o f ROSs attack foreign objects, against which they
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Fig. (5). The numerical value of alkali-labile DNA damages of PBLs from normal patients (the control group) being blood donors of Regional 
Centers of Blood Donation and Blood Therapy and PBLs from CVI patients (**p < 0.001).
Fig. (6). The numerical value of oxidative DNA damages of PBLs from normal patients (the control group) being a blood donors of Regional 
Centers of Blood Donation and Blood Therapy and PBLs from CVI patients (**p < 0.001).
Fig. (7). PBLs from normal volunteers (A) (n = 30) [control] and CVI patients [n = 30] (B) subjected to Fpg enzyme (0.1 /ml); % DNA 
(Head) -  84.4, % DNA (Tail) -  15.6; The amount of oxidative DNA damages presented as a percentage of DNA, that left comet’s head and 
was found in comet’s tail after electrophoresis (DNA, %).
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Fig. (8). The numerical value of alkali-labile/oxidative DNA damages of PBLs from normal patients (the control group) being a blood donors 
of Regional Centers of Blood Donation and Blood Therapy, and PBLs from CVI patients applying (one tablet twice a day) and not applying 
Detralex (**p < 0.001 vs. control).
Fig. (9). Three PBLs from CVI patients [n = 30], who were applying Detralex (one tablet twice a day); % DNA (Head) -  88.9, % DNA (Tail) 
-  11.1 and were not; % DNA (Head) -  74.8, %DNA(Tail) -  25.2, subjected to Fpg (0.1 /ml). Number of oxidative DNA damages is presented 
as the percentage of DNA that left comet’s head and was found in comet’s tail after electrophoresis (DNA, %).
are formed; however, remaining ROSs are flowing in ex­
tracellular fluids where they encounter other cells. In sites, 
where local inflammatory process is occurring on and many 
stimulated phagocytes are accumulated, concentrations of 
released ROSs may be high. The inflammatory reaction has a 
mechanism of positive feedback; exposure o f plasma to ac­
tion o f activated phagocytes results in generation of chemo- 
tactic factors and activating new lymphocytes [11]. Genera­
tion of chemotactic factors is inhibited by SOD. It might 
mean that the factor responsible for SOD generation is O- 2  
[12]. During the course of CVI, an increase in the level o f 
hemosiderin related to Fe metabolism is observed.
In Haber-Weiss reaction, in the presence of free iron 
ions, with the participation of reactive biologically partially 
reduced oxygen forms (O2- and H2O2), an O H  free radical is 
formed, which can react with every biological molecule be­
ing in its direct neighborhood.
Fe2+ + H2O2 ^  Fe3+ + O H  + O H
Fe3+ + O2 - ^  Fe2+ + O2
The O H  radical is strictly reactive, its cytotoxic effect 
also concerns DNA molecules, causing breaks in DNA 
strands (forming 8-hydroxy-2’-deoxyguanosine) [13].
In case of CVI, a relationship can be noticed between the 
level o f oxidative DNA damages and the level o f iron ions 
localized in the tissues. Such observations were made by 
Anna Jabłońska and coworkers (oxidative stress in patients 
with CVD. - Jabłońska P., Krzysciak W. et al., 2010 Central 
o f European Congress of Life Sciences, Krakow, Poland 20­
22 Sep.), where they noticed increased level o f Fe concentra­
tion in varicose veins in comparison to sufficient vessels, 
30.9% and 197.16% respectively. These observations can be 
explained by the function, which is played by iron in CVI 
condition. This increase was significantly correlated with 
oxidative DNA damages o f blood lymphocytes of CVI pa­
tients, which was observed by Wirginia Krzysciak, PhD 
(oxidative DNA damage in blood of CVD patients taking 
Detralex. - Krzysciak W. et al., 2010 Central o f European 
Congress of Life Sciences, Krakow, Poland 20--22 Sep.). 
This can be explained by growing concentration of free iron 
catalyses changes during Haber-Weiss reaction, in which 
O H  is formed. Huge amount o f hydroxyl radical results 
in disorders o f tissue functions, cells damage, destruction 
o f proteins, lipids, carbohydrates as well as DNA. It has 
influence on oxidative stress, being one of the causes o f 
CVI. Similar observations were made by Zamboni et al.
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They found increased extraction of hemosiderin with urine 
in patients with diagnosed vein pathology.
During free radical reaction, purine bases belonging to 
DNA can be oxidized, especially at position 8 of purine ring. 
One of the products formed in the aftermath of this reaction 
is 8-hydroxy-2-deoxyguanosine nucleoside.
Higher number of oxidative DNA damages is seen in 
acute lymphoblastic leukemia [14] where urine level of 8 -  
hydroxy-2’ -deoxyguanosine (8-OH-dG) increased. The 
level of oxidative DNA damages increases by 50% in normal 
volunteers with simultaneous decrease of antioxidative pro­
tection because of decrease of vitamin C level (from the 
level of 250 mg/day to 5 mg/day). Oxidative DNA damages 
increases by 50% [15]. Oxidative DNA damages accompany 
numerous diseases where ROSs play important role. Above 
mentioned phenomenon is presented in Table 1.
2. Impact of Micronized Purified Flavonoid Fraction 
(MPFF) - Detralex on Level of Alkali-Labile/Oxidative 
DNA Damages in a Group of CVI Patients
Hypothesis about protective effect of flavonoids, compo­
nents of Detralex (diosmin, hesperidin) on oxidative DNA
Table 1. Diseases where Increased Level of Oxidative DNA Damages was Observed
Disease Dna Damage Comment
Acute Lymphoblastic leukemia
FapyGua, 8-OH-Gua, 
FapyAde, 8-OHAde, 
5-OH-Cyt, 
5-OH-5-MeHyd, 
5-OH-Hyda (DNA
Significant increase in DNA damage level in ALL in comparison to control 
(p < 0.05) [20].
Parkinson's disease
8-OH-dG
8-OH-Guo (DNA/RNA)
Significant increase in 8-OH-dG level (p = 0.0002) in grey matter o f  brain [21].
Alzheimer's disease 8-OH-dG Higher 8-0H-dG level in cortex and cerebellum [22].
Amyotrophic lateral sclerosis 8-OH-dG Significant increase in 8-OH-dG level in comparison to control [23].
Primary breast cancer 8-OH-dG (DNA)
Increased 8-OH-dG level ( p < 0.0001) in carcinoma tissues in comparison to normal 
tissues [24].
Cardio-vascular diseases 8-OH-dG (DNA) Increased 8-OH-dG level in lymphocytes (p < 0.01) in ischaemic heart disease [25].
Colorectal carcinoma 8-OH-dG (DNA)
Significant increase in 8-OH-dG level in carcinoma tissue in comparison to normal 
mucous membrane [26].
Gynecological neoplasms 8-OH-dG (urine)
Significant increase in 8-OH-dG level (p < 0.05) in patients with cancer in relation to 
control [25].
Cervical carcinoma 8-OH-dG (DNA) Significant increase in 8-OH-dG level in comparison to control [27].
Renal cell carcinoma 8-OH-dG (DNA)
Significant increase in 8-OH level (p < 0.0005) in tissues changed in comparison to 
normal tissues [28].
Chronic liver disease 8-OH-dG (DNA) Significant increase in 8-OH-dG level (p < 0.05) in comparison to control [29].
HCV 8-OH-dG (DNA) Significant increase in 8-OH-dG level ( p<  0.001) in comparison to control [30].
Cystic fibrosis 8-OH-dG (urine) Increased level o f  8-OH-dG in comparison to control [31].
Small cell lung carcinoma 8-OH-dG (urine) Increase in 8-OH-dG level in comparison to control (p < 0.05) [32].
Pulmonary carcinoma 8-OH-dG (DNA) Increase in 8-OH-dG level in lymphocytes and carcinoma tissues [33].
Atopic dermatitis 8-OH-dG (urine) Increase in 8-OH-dG level (p < 0.0001) in comparison to control [34].
Gastric adenoma 8-OH-dG (DNA)
Significant increase in 8-OH-dG level in cancer tissues in comparison to normal 
tissues [35].
Type I and II diabetes 8-OH-dG (urine)
Level o f  8-OH-dG in patients with type I and II diabetes significantly increased in 
comparison to control [36].
Down syndrome 8-OH-dG (urine) Increase o f  8-OH-dG level in patients in comparison to control [37].
Rheumatoid arthritis 8-OH-dG (urine) Increase o f  8-OH-dG level ( p<  0.001) in comparison to control [38].
Chronic venous disease 8-OH-dG (DNA) Increase o f  8-OH-dG level (p < 0.00001) in comparison to control [own studies]
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damages of lymphocytes from CVI patients was confirmed. 
Application of Detralex in CVI patients contributes to 
decrease in oxidative DNA damages.
Antioxidative properties of Detralex result from its 
chemical structure. Due to chelating metal ions, Fe and Cu, 
this formulation protects cells from peroxidation of lipids in 
cell membranes. Components of the formulation have strong 
antioxidative potential, higher than vitamin C [16].
Hesperidin and diosmin act as anti-inflammatory com­
pounds, inhibiting activity of adhesion molecules and neu­
trophils, thus decreasing the inflammatory state [17]. Com­
ponents of Detralex characterize with broad spectrum of ac­
tion such as: antioxidative, anti-inflammatory, antiallergenic, 
anticarcinogenic, and have protective effect on vessels [18]. 
They are good chelators of free radicals because of reactivity 
of their hydroxyl groups. Due to binding metal ions, they 
inhibit Fenton reaction and thus limit DNA damage. Studies 
demonstrated that consumption of flavonoids could decrease 
risk of breast, colon, lung, trachea, oral cavity, and prostate 
cancers. Beneficial properties of hesperidin were also ob­
served in the context of liposaccharides, cell apoptosis 
through activation of caspase 3 in colorectal carcinoma and 
nicotinic toxicity of lungs. There are studies that show the 
function of hesperidin in treatment of liver damages related 
to oxidative stress [19]. It our studies demonstrated that ap­
plication of Detralex in CVI patients (one tablet two times 
daily) decreases the level of oxidative DNA damages. The 
analysis demonstrated statistically significant differences 
between CVI patients taking Detralex and patients not 
included into the therapy using this drug. Patients taking 
Detralex demonstrated lower level of alkali-labile/oxidative 
damages. The results showed significant correlation between 
phlebotropic drug (Detralex) and decrease in the level of 
alkali-labile/oxidative DNA damages.
No publications are available in databases that might 
report this phenomenon and enable comparison of obtained 
results. Thus, obtained results indicated about uniqueness of 
carried out studies, which demonstrate the impact of 
Detralex on the level of DNA damages and show new facts 
in the problem of CVI pathogenesis and its therapy.
CONCLUSIONS
In CVI patients, oxidative DNA damages indicate on 
proceeding oxidative stress. Application of Detralex con­
firms antioxidative action of its components (hesperidin and 
disomin). Correlation between decrease of the level of oxida­
tive DNA damages and application of Detralex proves effec­
tiveness of MPFF in prevention and treatment of CVI.
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ABBREVIATIONS
CEAP = Clinical state, etiology, anatomy and patho­
physiology
USG = Ultrasonography
FDA = Fluorescein diacetate
EtBr = Ethidium bromide
CVDs = Chronic venous diseases
CVI = Chronic venous insufficiency
ROS = Reactive oxygen species
RNS = Reactive nitrogen species
O2 - ' = Superoxide anion
OH' = Hydroxyl radical
HO 2 ' = Hydroperoxide radical
H 2 O2  = Hydroxy peroxide
O2 ' = Oxygen singlet
8-oxo-Gua = 8-Oxoguanine
HmUra = 5-Hydroxymethyluracil
BER = Base-excision repair
API = Active pharmaceutical ingredient
GST = Glutathione S-transferase
K 2 EDTA = Ethylenediaminetetraacetic acid dipotas­
sium salt
PBS = Phosphate buffered saline
FBS = Fetal bovine serum
DMSO = Dimethyl sulfoxide
LMPA = Low melting point agarose
NMPA = Normal melting point agarose
Fpg = Formamidopyrimidine DNA glycosylase
HEPE S = [4 - (2 -hy droxy ethy l) -1 -
piperazineethanesulfonic acid]
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